ASH Q4 Earnings Miss Estimates Despite Strong Segment Growth

Zacks
Zacks kaynağında aç
ASH Q4 Earnings Miss Estimates Despite Strong Segment Growth

Ashland Inc. ASH reported adjusted earnings of $1.12 per share, excluding intangible amortization, for the fourth quarter of fiscal 2026, up 3.7% from $1.08 in the year-ago quarter. The bottom line missed the Zacks Consensus Estimate of $1.3 by 13.8%.

Sales increased 4.2% year over year to $498 million, missing the Zacks Consensus Estimate of $500.7 million by 0.5%. Sales volumes rose 3%, led by growth in pharmaceuticals, personal care, coatings and performance specialties. Pricing increased 2%, while unfavorable currency movements reduced sales by $3 million.

Ashland Inc. Price, Consensus and EPS Surprise

Ashland Inc. Price, Consensus and EPS Surprise

Ashland Inc. price-consensus-eps-surprise-chart | Ashland Inc. Quote

ASH's Segment Highlights

Life Sciences: Sales increased 4% year over year to $180 million in the reported quarter. The figure missed the Zacks Consensus Estimate of $184 million. Growth was driven by higher volumes, broad-based pharmaceutical demand across major regions and technology platforms, including injectables, cellulosics and film coatings. Pharmaceutical sales rose approximately 6%, marking the sixth consecutive quarter of year-over-year volume growth. Nutrition sales declined slightly due to lower volumes.

Personal Care: Sales increased 8% year over year to $163 million from $151 million. The metric beat the consensus estimate of $158 million. Growth reflected strong demand for biofunctional actives and microbial protection, both recording double-digit gains. Hair care sales increased at a double-digit rate, while skin care registered high-single-digit growth. These gains were partly offset by low-single-digit declines in oral care and household sales.

Specialty Additives: Sales remained flat year over year at $131 million and missed the Zacks Consensus Estimate of $139 million. Coatings and performance specialties sales increased 9% and 14%, respectively, supported by favorable volumes, pricing and market-share gains. However, weak demand in energy and resources and lower construction volumes, resulting from deliberate portfolio actions, offset these improvements.

Intermediates: Sales remained unchanged year over year at $33 million. Merchant sales increased 4% to $24 million, supported by favorable product mix, higher N-Methyl-2-pyrrolidone sales and improved pricing. These gains were partly offset by lower merchant butanediol volumes and a $1 million decline in captive sales to $9 million.

ASH's Financial Position and Cash Flow

Cash flows provided by operating activities increased to $90 million from $40 million in the year-ago quarter, primarily reflecting lower working capital. Ongoing free cash flow rose to $74 million from $52 million, with conversion improving to 61% from 44%.

Ashland ended fiscal 2026 with approximately $480 million in cash, total liquidity of $976 million and net debt of $891 million. Net leverage stood at 2.3 times, within the company's long-term target range.

For the full fiscal year, operating cash flow increased to $385 million from $134 million, supported by inventory reductions and improved working-capital management. Ongoing free cash flow reached $232 million, compared with $127 million in fiscal 2025.

Ashland's Fiscal 2027 Outlook

For fiscal 2027, Ashland expects sales between $1.905 billion and $1.975 billion, representing anticipated growth of approximately 2-6% year over year. Adjusted EBITDA is projected between $405 million and $435 million.

Management expects ongoing free cash flow conversion to exceed 40% of adjusted EBITDA, with capital expenditures reaching up to approximately $140 million. Foreign currency movements are expected to create headwinds of $20-$25 million to sales and $7-$10 million to adjusted EBITDA.

The company anticipates resilient demand in Life Sciences and Personal Care, continued momentum in coatings and performance specialties, and additional Intermediates volumes from energy-storage customers.

ASH’s Price Performance

Shares of Ashland have gained 55.2% over the past year compared with the 15% rise in its industry. 

Zacks Investment Research
Image Source: Zacks Investment Research

ASH’s Zacks Rank & Key Picks

ASH currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Reliance, Inc. RS, Element Solutions Inc. ESI and Worthington Steel, Inc. WS.

RS and ESI currently sport a Zacks Rank #1 (Strong Buy) each, while WS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $26.54 per share, indicating an 86.1% year-over-year surge. RSshares have gained 55.7% over the past year.

The Zacks Consensus Estimate for ESI’s 2026 earnings is pegged at $1.85 per share, indicating a year-over-year rise of 24.2%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 6%.

The Zacks Consensus Estimate for WS’ current fiscal-year earnings is pinned at $4.07 per share. WSshares have gained 24% over the past year.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Ashland Inc. (ASH): Free Stock Analysis Report
 
Element Solutions Inc. (ESI): Free Stock Analysis Report
 
Reliance, Inc. (RS): Free Stock Analysis Report
 
Worthington Steel, Inc. (WS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research